Showing results (31-40 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 6, 2016
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cellsBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Investigational New Drugs|March 20, 2016
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancersAndrew L Coveler, Andrew H Ko, Daniel V T Catenacci, et al.
Investigational New Drugs|March 22, 2016
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerShivaani Kummar, James L Wade, Amit M Oza, et al.
Investigational New Drugs|February 20, 2016
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinibLinda Mahjoubi, Anas Gazzah, Benjamin Besse, et al.
Investigational New Drugs|November 8, 2017
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancerSang Eun Park, Ha-Gyeong Kim, Dong Eun Kim, et al.
Investigational New Drugs|November 10, 2017
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinomaGlen J Weiss, Lisa Blaydorn, Julia Beck, et al.
Investigational New Drugs|July 30, 2016
Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary reportMagdalena Kusaczuk, Rafał Krętowski, Anna Stypułkowska, et al.
Investigational New Drugs|July 30, 2016
The renal effects of ALK inhibitorsHassan Izzedine, Rania Kheder El-Fekih, Mark A Perazella
Investigational New Drugs|February 11, 2025
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanomaLu Yang, Yanlong Feng, Xuewen Liu, et al.
Investigational New Drugs|March 5, 2025
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphomaMelissa Johnson, David Hong, Irene Braña, et al.
Pageof 372